Ge Longhui 21st November丨Bio-Thera Solutions (688177.SH) stated on the interactive platform that the company's Bevacizumab monoclonal antibody has not yet started sales in the European Union and USA; TOFIDENCE (Tuzumab monoclonal antibody) started sales in the USA in May this year, and the listing time in the European Union is yet to be determined. Other overseas markets have not yet been approved for listing, and the company will actively follow up to promote the relevant processes. The company recognizes revenue in accordance with accounting standards, and part of the 10 million milestone from Hikma is included in the revenue. For specific information on the breakdown of revenue, please refer to the company's disclosure in the "Bio-Thera Solutions 2024 Interim Report" in statutory media.